Matthew Ronsheim

Route 53 Outlook Microsoft Office 365 Microsoft Azure Hosting WordPress.org New Relic Mobile Friendly Piwik Nginx Google Analytics Google Tag Manager Remote AI

drug discovery ion channels neurology epilepsy drug development neuroscience biotechnology biopharmaceuticals seizures focal onset seizures mdd psychiatry depression neuropsychiatry tonicclonic seizures fos pgtsc sodium channels potassium channels biotechnology: pharmaceutical preparations health care biotechnology research therapeutics innovative medicines kv7 potassium channel ion channel drug discovery clinical trials preclinical programs mental health psychiatric disorders drug commercialization medicinal chemistry patient care neurological disorders clinical efficacy safety studies medical affairs investor relations corporate governance pharmacology channelopathies neurodegenerative diseases pharmaceutical industry clinical development onboarding process employee benefits career opportunities collaborative culture ethical practices research & development stakeholder engagement regulatory compliance market analysis capital markets orphan diseases scientific expertise healthcare conferences long-term clinical data expanded access program medical publications employee training innovative therapeutics kcnq2 developmental & epileptic encephalopathy kv7 potassium channel opener orphan drug designations rare diseases high unmet medical need healthcare providers pharmaceutical partners ion channel modulators partnerships patient populations precision therapies burnaby boston collaborations market positioning niche markets therapeutic focus healthcare solutions drug candidates clinical-stage company commercial operations health wellness & fitness hospital & health care financial services